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Abstract
In the U.S., guidelines recommend that women continue mammography screening until at least 
age 74, but recent evidence suggests declining screening rates in older women. We estimated 
adherence to screening mammography and multilevel factors associated with adherence in a 
longitudinal cohort of older women. Women aged 66–75 years receiving screening mammography 
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within the Breast Cancer Surveillance Consortium were linked to Medicare claims (2005–2010). 
Claims data identified baseline adherence, defined as receiving subsequent mammography within 
approximately 2 years, and length of time adherent to guidelines. Characteristics associated with 
adherence were investigated using logistic and Cox proportional hazards regression models. 
Analyses were stratified by age to investigate variation in relationships between patient factors and 
adherence. Among 49,775 women, 89% were adherent at baseline. Among women 66–70 years, 
those with less than a high school education were more likely to be non-adherent at baseline (odds 
ratio [OR] 1.96; 95% confidence interval [CI] 1.65–2.33) and remain adherent for less time 
(hazard ratio [HR] 1.41; 95% CI 1.11–1.80) compared to women with a college degree. Women 
with ≥1 versus no Charlson co-morbidities were more likely to be non-adherent at baseline (OR 
1.46; 95% CI 1.31–1.62) and remain adherent for less time (HR 1.44; 95% CI 1.24–1.66). Women 
aged 71–75 had lower adherence overall, but factors associated with non-adherence were similar. 
In summary, adherence to guidelines is high among Medicare-enrolled women in the U.S. 
receiving screening mammography. Efforts are needed to ensure that vulnerable populations attain 
these same high levels of adherence.
Introduction
Screening mammography is recommended by professional society guidelines and supported 
by organized screening programs in many developed countries. For instance, the European 
Union cancer screening policy recommends biennial screening from age 50–69 years 
(Council of the European Union, 2003). Similarly, in the U.K., the National Health Service 
Breast Screening Programme invites women to screen from age 50–70 years (Public Health 
England, 2016). In the U.S., screening mammography is recommended for older women 
until at least age 74 years (Siu, 2016) or for as long as a woman is in good health (Oeffinger 
et al., 2015). Because U.S. women often continue to screen well beyond age 70 (Ryerson et 
al., 2008), the U.S. provides a unique context in which to investigate factors related to 
screening mammography use in older women. This has the potential to inform proposed 
expansion of the screening age range in other countries as has been proposed for the UK 
(Moser et al., 2011).
In the U.S., screening mammography use increased sharply from the mid-1990s through 
2005 (Breen et al., 2007; Rao et al., 2008). However, studies including data after 2005 have 
produced conflicting results with some indicating a continued increase in mammography use 
while others suggest a stabilization or possible decline (Breen et al., 2011; Breen et al., 
2007; Pace et al., 2013; Sprague et al., 2014). Some evidence suggests that the 2009 U.S. 
Preventive Services Task Force (USPSTF) breast cancer screening recommendations calling 
for biennial screening may have contributed to a decline in mammography use among older 
women (Jiang et al., 2015b). Understanding multilevel characteristics associated with a 
possible decline is key to ensuring that the benefits of screening reach as many women as 
possible, particularly older women of screening age, given the increased risk of breast cancer 
in this group.
A variety of studies have investigated characteristics associated with participation in 
screening mammography. European national screening program registries have identified 
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demographic characteristics including lower socio-economic status and older age as factors 
associated with non-attendance (Aarts et al., 2011; Bulliard et al., 2004a; Lagerlund et al., 
2002). In the U.S., characteristics including non-white race, increased burden of co-morbid 
disease, and lower socio-economic status have been associated with lower rates of screening 
(Blanchard et al., 2004; Koya et al., 2011). Older age is also associated with significantly 
lower rates of mammography utilization (Jiang et al., 2015a; Koya et al., 2011). Women 
receiving other preventive services are more likely to receive screening mammography 
(Koya et al., 2011). The majority of these findings were based on national surveys and cross-
sectional studies using Medicare claims to identify characteristics associated with a single 
episode of screening mammography use. Relatively few studies have investigated 
characteristics associated with adherence to screening guidelines across multiple screening 
rounds (Blanchard et al., 2004).
We analyzed the association between participant characteristics and adherence to screening 
mammography guidelines across multiple rounds of screening in a U.S. cohort of Medicare-
enrolled women aged 66–75 years. We followed individual women longitudinally to 
determine if and when they discontinued screening. Continued adherence, as compared to 
participation in only a single round, is necessary to ensure that the potential benefits of 
screening are realized. We hypothesized that women who had received prior screening 
would remain adherent across multiple rounds of screening at high rates. Based on reports 
that adherence rates vary by age, and that factors such as family history affect adherence 
differently by age, we hypothesized that, as women approach age limits recommended for 
cessation of screening, the factors influencing adherence to mammography 
recommendations might vary.
Methods
Data sources
Data were obtained from four Breast Cancer Surveillance Consortium (BCSC) 
mammography registries (http://breastscreening.cancer.gov) (Ballard-Barbash et al., 1997) 
that linked to Medicare claims data: New Hampshire Mammography Network, Carolina 
Mammography Registry, San Francisco Mammography Registry, and Vermont Breast 
Cancer Surveillance System. Registries collected data from community radiology facilities, 
including patient characteristics and clinical information at each mammogram. Breast cancer 
diagnoses were obtained by linking BCSC data to pathology services, regional Surveillance, 
Epidemiology, and End Results programs, and state tumor registries. Data were pooled at a 
central Statistical Coordinating Center (SCC). Registries and the SCC received Institutional 
Review Board approval for active or passive consenting processes or a waiver of consent to 
enroll participants, link data, and perform analysis. All research procedures were Health 
Insurance Portability and Accountability Act compliant, and registries and the Statistical 
Coordinating Center received a Federal Certificate of Confidentiality and other protections 
for the identities of women, physicians, and facilities.
For women who were enrolled in Medicare between 2005 and 2010 and who received 
mammograms at one of the four BCSC registries, information on health services use was 
obtained through linkage to the Centers for Medicare and Medicaid Services’ (CMS) 
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Medicare Program Master Enrollment file using sex, name, birth date, death date, and social 
security number. Most U.S. adults over age 65 are enrolled in Medicare Part A, making the 
Medicare enrolled population broadly representative of older adults. The majority (86%) of 
BCSC women aged 65 and older were successfully linked to Medicare claims data. Failure 
to link to Medicare claims was most commonly due to lack of information on social security 
number, an identifier that was not available for some participating facilities. Medicare 
eligibility and enrollment information for this period as well as all claims data for Medicare-
covered services were included in the database.
Study population
Women receiving a screening mammogram between January 1, 2005 and July 1, 2008 
within one of the four participating BCSC registries were included if they met these criteria: 
age 66–75 years at the screening mammogram; continuously enrolled in Medicare Parts A 
and B and not enrolled in a Medicare managed care plan from 1 year before to 30 months 
after the screening mammogram; no history of breast cancer; and did not die or have a 
diagnosis of invasive carcinoma or ductal carcinoma in situ within 30 months after the 
screening mammogram. Each woman’s first eligible screening mammogram during the 
study period was defined as the “index” mammogram. At the time of the index 
mammogram, we required the woman to be age 66 years or older with 1 prior year of 
continuous Medicare enrollment to facilitate computation of healthcare utilization and co-
morbidity scores. We required 30 months of continuous Medicare enrollment after the index 
mammogram to ensure capture of subsequent mammography. We excluded women enrolled 
in a Medicare managed care plan because these plans are not required to submit itemized 
claims to CMS; capture of services for these women is expected to be incomplete. We 
excluded index mammograms in the BCSC database if a corresponding Medicare claim for a 
mammogram could not be found within 7 days before or after the recorded exam date.
Measures and definitions
At each BCSC mammogram, women completed a self-administered questionnaire that 
included age, race/ethnicity, educational attainment, family history of breast cancer in a first-
degree relative, and previous mammography. Based on factors ascertained at the index 
mammogram, we computed the BCSC 5-year breast cancer risk score (Tice et al., 2008).
Women were linked to census-based community-level characteristics from the 2010 
Environmental Systems Research Institute business analyst application by geocoding their 
residential address and joining the location to U.S. Census units (Environmental Systems 
Research Institute, 2014). Community characteristics included the proportion of individuals 
in the census tract who were linguistically isolated (residing in a household in which no one 
age 14 years old or over (a) speaks only English or (b) speaks a non-English language and 
speaks English “very well”), and, at the census block group level: diversity index (a measure 
of the racial and ethnic diversity of a geographic area ranging from 0 (no diversity) to 100 
(complete diversity)), median disposable income, median household income, average annual 
health insurance expenditures, average annual public transportation expenditures, proportion 
with a college degree, proportion with access to the internet, proportion that read health 
magazines, and proportion that read a newspaper daily. These factors were selected because 
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they related to health literacy, potential barriers to use of health services due to 
transportation issues, or socioeconomic characteristics previously found to be associated 
with use of preventive services.
We identified mammograms using Medicare claims in the Inpatient, Outpatient, and Carrier 
files. Mammography claims were identified based on International Classification of 
Diseases, Ninth Revision procedure codes and Health Care Common Procedure Coding 
System codes (see Supplementary Table S1). Claims codes for both screening and diagnostic 
mammograms were included to allow for the possibility that a woman might forego a 
screening mammogram if she had recently received a diagnostic mammogram. Beginning at 
the time of a woman’s index mammogram, we identified all subsequent mammograms.. We 
also used Medicare claims data from the year before the index mammogram to calculate the 
Klabunde modification to the Charlson co-morbidity score (Klabunde et al., 2000). We 
identified hospitalizations in the year before the index mammogram based on the presence 
of any inpatient claims. Similar to prior studies (Brawarsky et al., 2012; Earle et al., 2003; 
Kronman et al., 2008; Schootman et al., 2008), we identified primary care visits in the year 
before the index mammogram based on the presence of claims in the Carrier file with 
Healthcare Financing Administration codes: 01 (general practice), 11 (internal medicine), 08 
(family practice), 16 (obstetrics/gynecology), 38 (geriatric medicine), and 70 (multispecialty 
group practices).
We defined two outcomes related to adherence to screening mammography. First, we 
defined baseline adherence as a binary indicator of whether the woman received subsequent 
mammography 9–30 months after the index mammogram. Because guidelines relating to 
screening mammography are inconsistent with respect to the recommended screening 
interval (Oeffinger et al., 2015; Siu, 2016), we conservatively allowed a 30-month window 
in which to receive subsequent mammography corresponding to the maximum 
recommended interval (24 months) and allowing an additional 6 months to accommodate 
deviation from recommendations due to scheduling or other logistical difficulties. We 
excluded the first 9 months following the screening mammogram to remove diagnostic 
mammograms received as follow-up for a positive index mammogram. Second, among 
women who were adherent at baseline (received a second mammogram within 30 months of 
the index mammogram), we ascertained a measure of longitudinal adherence, the length of 
time they remained adherent to screening recommendations. This measure is defined as the 
time from the index mammogram to the end of the first 30-month gap in mammography. By 
definition, women who were eligible for inclusion in the longitudinal analysis had a 
mammogram at least 9 months after their index mammogram. This post-index mammogram 
conferred an additional 30 months of adherence. Therefore, all women in the longitudinal 
analysis were adherent for at least 39 months after their index mammogram. Accordingly, 
longitudinal follow-up began 39 months after the index mammogram. Supplementary Figure 
S2 illustrates the definitions of our adherence measures. Our analysis focused on the length 
of time women remained adherent rather than the number of screening rounds they 
participated in because this directly informs the amount of person-time “covered” by 
screening in the population (Chubak and Hubbard, 2016).
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Statistical analysis
We calculated counts and proportions for woman-level characteristics stratified by baseline 
adherence and estimated the proportion of women who were non-adherent in sub-groups 
defined by these characteristics stratified by age (66–70 and 71–75 years). We used 
multivariable logistic regression to analyze the association between characteristics and 
baseline non-adherence stratified by age group. Next, we analyzed longitudinal adherence 
using survival methods. Beginning 39 months after the index mammogram (the first date at 
which it was possible for a woman to become non-adherent), we constructed Kaplan-Meier 
curves for the time to the first period of non-adherence. Follow-up for screening 
mammography use continued until the earliest occurrence of death, disenrollment from 
Medicare parts A or B, enrollment in a Medicare managed care plan, breast cancer 
diagnosis, or the end of study follow-up, December 31, 2010. We used Cox proportional 
hazards models to analyze factors associated with increased hazard of non-adherence to 
screening mammography guidelines. We estimated adjusted hazard ratios for participant 
characteristics associated with non-adherence. Separate models were estimated for women 
66–70 and 71–75 years old at the index mammogram. Models were adjusted for all 
participant characteristics, exam year, and BCSC registry and were estimated using complete 
case analysis.
Statistical significance was evaluated at the two-sided alpha = 0.05 level. Analyses were 
conducted using Stata (Stata Statistical Software: Release 12. College Station, TX: 
StataCorp LP).
Results
Our cohort included 49,775 women. Reasons for exclusion are summarized in 
Supplementary Figure S3. In our sample, 44,119 (88.6%) women were adherent at baseline 
(received a mammogram between 9 and 30 months after the index mammogram). Most 
(60.8%) were age 66–70 years at the index mammogram. Women who were adherent at 
baseline tended to be younger, have higher educational attainment, come from communities 
with higher average health insurance expenditures, and were more likely to have a family 
history of breast cancer, 5-year BCSC breast cancer risk score > 2.5%, Charlson co-
morbidity score of 0, and a primary care visit in the prior year compared with women who 
were non-adherent (Table 1).
At baseline, non-adherence was 20% or less across all participant sub-groups investigated. 
The highest observed level of non-adherence (20%) was among women age 66–70 years 
with a 5-year breast cancer risk score less than 1% (Table 2, Supplementary Figure S4). 
Based on multivariable logistic regression models in both the older (71–75 years) and 
younger (66–70 years) age groups, women with less education were more likely to be non-
adherent and those with higher breast cancer risk scores and residing in communities with a 
higher proportion of newspaper readership were less likely to be non-adherent. In the 66–70 
year old age group, older age, Charlson co-morbidity scores greater than 0, and lack of a 
primary care visit in the prior year were associated with increased odds of non-adherence, 
while residing in communities with greater average public transportation expenditures was 
associated with decreased odds of non-adherence. In the 71–75 year old age group, women 
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living in communities with a higher diversity index and higher median household incomes 
were less likely to be non-adherent (Table 2, Supplementary Figure S5).
Women included in our longitudinal analysis were followed for a median of 60.1 months 
after the index mammogram (interquartile range: 50.7–65.6). Women 71–75 years old 
remained adherent to screening for slightly less time than did women 66–70 years old 
(Figure 1). After 30 months of longitudinal follow-up (69 months after the index exam), 
89.1% (95% confidence interval [CI]: 88.4–89.7) of women 66–70 years old remained 
adherent compared with 85.4% (95% CI, 84.6–86.2%) of women 71–75 years old. Risk 
factors associated with shorter time to non-adherence were similar in the two age groups 
(Table 3, Supplementary Figures S6 and S7). For both age groups, the hazard ratio (HR) for 
non-adherence was higher among older women, those with less education, and those with a 
co-morbidity score greater than 0. In the younger age group, having a hospitalization in the 
prior year was also associated with an increased hazard of non-adherence. Residing in a 
community with median household income in the highest quartile was associated with a 
decreased hazard of non-adherence in the 66–70 year old age group. Among women 71–75, 
women from neighborhoods with greater diversity and in the highest quartile of expenditures 
on public transportation as well as women with 5-year breast cancer risk >2.5% had 
decreased hazards of non-adherence.
Discussion
Using longitudinal data from Medicare claims on mammography utilization, we identified 
patterns of adherence to screening mammography recommendations and factors associated 
with non-adherence in a cohort of older women in the U.S. In general, adherence was high 
in this cohort both at baseline and longitudinally. Almost 90% of women received a 
mammogram within 30 months of their index examination and, among these women, more 
than 85% remained adherent throughout the study follow-up period. Overall, this indicates 
that among U.S. women continuously enrolled in fee-for-service Medicare who have 
received a prior mammogram, levels of continued participation in screening mammography 
are very high.
We found that women aged 71–75 years had lower levels of adherence than women aged 
66–70 years. While screening practices are unlikely to change abruptly or uniformly at age 
70, we hypothesized that, as women approach the upper boundary of the recommended 
screening age range, factors associated with screening adherence might vary. Lower 
screening adherence levels among women over 70 years of age may represent appropriate 
cessation of screening as women experience greater co-morbid disease burden or approach 
74 years of age, the upper limit specified by some screening recommendations. As 
remaining life expectancy decreases, the probability of harm due to overdiagnosis and 
unnecessary treatment increases (Braithwaite et al., 2013; Walter and Covinsky, 2001; 
Walter and Schonberg, 2014). Recommendations have therefore emphasized individualized 
decision making about continued screening in older women based on life expectancy (Smith 
et al., 2003; Walter and Covinsky, 2001). Our results indicating that screening adherence 
increases with increasing breast cancer risk and decreases in relation to increased co-morbid 
disease burden and prior hospitalization suggest that women are receiving screening 
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mammography concordant with their individual balance of screening benefits and harms. 
These results are similar to prior findings that screening mammography utilization declines 
with increasing age and decreasing life expectancy (Koya et al., 2011; Schonberg et al., 
2013; Tan et al., 2012). Our findings relating to patterns of adherence in women over age 70 
years may help inform outreach efforts in the U.S. as well as efforts to expand screening to 
this older age range in countries with organized screening programs.
We identified demographic and community characteristics associated with (1) baseline non-
adherence and (2) shorter time to non-adherence. Women with lower educational attainment 
were more likely to be non-adherent at baseline and became non-adherent sooner when 
followed longitudinally. Among women 66–70, having a primary care visit in the year 
before the index mammogram was associated with baseline but not longitudinal adherence. 
The lack of observed association between primary care visits and longitudinal adherence 
may be due to changes in women’s use of primary care over time, which were not captured 
by our study. Previous studies have also found that characteristics including higher 
educational attainment and use of other preventive health care services were associated with 
higher cross-sectional rates of screening mammography use (Schonberg et al., 2013) and 
screening re-attendance (Bulliard et al., 2004b). Community characteristics associated with 
better adherence at baseline included residing in a community with a higher proportion of 
daily newspaper readership and, among older women, higher diversity index and higher 
median household income. Our study confirms and expands on prior results by 
demonstrating that, in a population of older women receiving screening mammography, the 
probability of remaining adherent to screening guidelines is decreased in population sub-
groups characterized by lower socioeconomic status.
Strengths of our study include its large size, inclusion of women from regional 
mammography registries throughout the U.S., and longitudinal follow-up. Additionally, the 
combination of detailed self-report and U.S. Census data on participant and community 
characteristics allowed us to investigate a broad range of factors that may influence 
mammography adherence. By linking these data to Medicare claims, we were able to 
identify all utilization of mammography after the index mammogram, as well as utilization 
of other healthcare services prior to baseline.
Our study also had several limitations. Because we have focused on a cohort of women 
continuously enrolled in fee-for-service Medicare, our results are not necessarily 
generalizable to women under 65 years, women enrolled in managed care plans, or those 
with intermittent Medicare enrollment. These women may differ in screening behavior or in 
characteristics associated with screening. For instance, women enrolled in managed care 
plans tend to be generally healthier than fee-for-service Medicare enrollees (Shimada et al., 
2009). Despite these limitations, the fee-for-service Medicare population includes over 30 
million U.S. women, making this a large and informative population to study. We have also 
defined “adherence” as receipt of any mammogram within 30 months, including both 
screening and diagnostic mammograms. While this provides an estimate of the proportion of 
women who are not in need of screening because they have received a recent mammogram, 
it overestimates the proportion of women who choose to participate in screening. We 
adopted this strategy in order to account for women foregoing screening due to a recent 
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diagnostic mammogram. Finally, we have identified characteristics associated with 
screening adherence, but there may be other factors not captured by our study that also 
influence screening. As such, our results describe screening mammography use patterns but 
should not be interpreted as causal relationships.
Conclusions
In conclusion, we found high levels of adherence to screening mammography 
recommendations among Medicare-enrolled U.S. women both at a single screening round 
and across multiple rounds of screening. Factors associated with adherence including 
younger age, lower Charlson co-morbidity score, and greater breast cancer risk suggest that 
women are making judicious choices about screening mammography, with continued use 
roughly corresponding to their likelihood of benefiting from screening. However, decreased 
screening among some socioeconomically vulnerable groups including women with lower 
educational attainment and women residing in communities with lower household incomes 
suggest that outreach is still needed to ensure that medically underserved populations receive 
guideline-concordant care.
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Highlights
• Medicare-enrolled women were highly adherent to screening 
mammography.
• Older age and increasing co-morbidity were associated with decreased 
adherence.
• Lower educational attainment and income were associated with 
decreased adherence.
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Figure 1. 
Kaplan-Meier estimates of proportion of women adherent to screening mammography 
recommendations by age at index mammogram among women in the Breast Cancer 
Surveillance Consortium-Medicare cohort receiving an index screening mammogram 
between January 1, 2005 and July 1, 2008. Follow-up begins 39 months after index 
mammogram.
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